Spanish Society of Medical Oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patients
Clin. transl. oncol. (Print)
; 11(7): 446-454, jul. 2009. ilus, tab
Article
em En
| IBECS
| ID: ibc-123657
Biblioteca responsável:
ES1.1
Localização: BNCS
ABSTRACT
Neutropenia is a common complication of cancer chemotherapy. Colony-stimulating factors (CSF) may be used to avoid neutropenia-associated complications. The Spanish Society of Medical Oncology (SEOM) recently constituted a working group to review the main issues concerning the use of CSF and carried out a consensus process about the use of CSF in cancer patients, held in Madrid on 26 May 2006. The group concluded the following recommendations: prophylactic use of CSF is recommended when a rate of febrile neutropenia (FN) higher than 20% is expected without the use of CSF or when additional risk factors for neutropenia exist; therapeutic use of CSF is recommended in order to treat FN episodes but not to treat afebrile neutropenic episodes. In addition, the use of CSF is considered effective when used to mobilise stem cells before high-dose chemotherapy and when used for chemotherapy schedule optimisation in dose-dense and in dose-intense regimens (AU)
Buscar no Google
Coleções:
06-national
/
ES
Base de dados:
IBECS
Assunto principal:
Fatores Estimuladores de Colônias
/
Neoplasias
/
Neutropenia
Tipo de estudo:
Etiology_studies
/
Guideline
/
Risk_factors_studies
Limite:
Female
/
Humans
/
Male
País/Região como assunto:
Europa
Idioma:
En
Revista:
Clin. transl. oncol. (Print)
Ano de publicação:
2009
Tipo de documento:
Article